Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirtazapine augmentation in schizophrenia patients treated with risperidone
ISRCTN54975957Phase 4Completed
- Sponsor
- Cambridge Health Alliance
- Start
- Oct 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of mirtazapine and risperidone in schizophrenia, sponsored by Cambridge Health Alliance. Primary endpoints: Positive and Negative Syndrome Scale at week 8, Scale for the Assessment of Negative Symptoms at week 8 and 2 more. Started Oct 2008; status: completed.
02
Drugs
mirtazapinerisperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on ISRCTN54975957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN54975957.